TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6470965
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (1500 mg of salicylate)
Study: 1400933
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) buserelin stopped on the same day as HMG treatment
Study: 20646350
Drug: Sublingual allergoid
Normalized name: Coccidioides immitis spherule
DrugBank: Coccidioides immitis spherule (DB11294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergoid immunotherapy (allergoid SLIT)
Study: 1311351
Drug: sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium stibogluconate (20 mg of antimony per kilogram per day intravenously for 20 days)
Study: 18019665
Drug: Obese individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obese individuals with insulin resistance
Study: 31743334
Drug: Anti-OSP antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-OSP antibody responses
Study: 17985420
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with MTX and infliximab (Group 4)
Study: 17985420
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with MTX, sulfasalazine, and prednisone (Group 3)
Study: 11896097
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no further therapy)
Study: 8512911
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT)
Study: 1559737
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine lotion
Study: 20652333
Drug: Landiolol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol at 30 μg/kg/min
Study: 1741200
Drug: Intermittent amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent amoxicillin
Study: 22342538
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 50 μg once daily
Study: 22859563
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time (OTT) ≥43 days
Study: 18294310
Drug: Oral alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin 30 mg once daily for up to 24 weeks
Study: 2425671
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase (UK) - 2.83 X 10(5) units by six-hour intravenous drip infusion
Study: 28274889
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000 IU monthly for 24 months
Study: 25196897
Drug: Simulated dosing
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated dosing regimens for rFVIIIFc
Study: 12925474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propacetamol 30 mg kg(‐1) and diclofenac 1.1 mg kg(‐1)
Study: 6884411
Drug: Sulphinpyrazone 800
Normalized name: Sulphinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphinpyrazone 800 mg daily
Study: 19078834
Drug: Periprocedural abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periprocedural abciximab treatment
Study: 28188240
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg once daily before breakfast for 24 weeks
Study: 7669649
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SDZ IMM 125 daily
Study: 2257964
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine taken twice daily
Study: 25574800
Drug: Sevoflurane at
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane at 0.5 MAC combined with remifentanil (0.25 to 0.35 μg/kg/min) and cisatracurium (0.03 to 0.04 mg/kg/h)
Study: 6105024
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose
Study: 10172545
Drug: Drug supply
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug supply and cost sharing system
Study: 26684635
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg)
Study: 21221770
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg every month
Study: 1556197
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (NT)
Study: 15771757
Drug: Ursofalk capsules
Normalized name: ursodiol Oral Capsule [Ursofalk]
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursofalk capsules
Study: 1658138
Drug: UK 79300
Normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 79300 100 mg every 12 h (group 2)
Study: 25730407
Drug: Grief-specific music
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grief-specific music therapy in addition to standard care
Study: 31287580
Drug: Daily full-body
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily full-body application of an emollient with ceramide and amino acids
Study: 28209746
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)
Study: 17513395
Drug: Meal A
Normalized name: Yardley Oatmeal and Almond Bath Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal A (50 g complete amino acid mixture without extra arginine)
Study: 31003681
Drug: Gua Sha
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gua Sha therapy (12 sessions, one session per week)
Study: 24468078
Drug: Aqueous gel
Normalized name: Sulfacetamide Sodium/Sulfur 10%-5% Topical application Gel/Jelly [ROSULA AQUEOUS GEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous gel
Study: 21982723
Drug: Sublingual testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone 0.75 mg
Study: 19886836
Drug: Control (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single-dose nevirapine)
Study: 17931758
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment
Study: 17209220
Drug: Vitamin supplements
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplements
Study: 15516023
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration via mini enema (local administration into the large intestine)
Study: 12950861
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR)
Study: 2657058
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg once daily
Study: 1746458
Drug: Felodipine 20
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 20 mg once daily
Study: 1746458
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg four times daily
Study: 1746458
Drug: Felodipine 20
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 20 mg once daily (follow-up)
Study: 30513231
Drug: ADHD-specific drugs
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD-specific drugs combined with SUD treatments
Study: 30513231
Drug: Pharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatments for ADHD
Study: 17724363
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg i.v. pantoprazole infused for 2 minutes
Study: 9778080
Drug: Double-bolus alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-bolus alteplase (two 50 mg bolus injections 30 minutes apart)
Study: 11579072
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (twice weekly Osteofit classes for 10 weeks)
Study: 25922978
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml bupivacaine with 100 μg of fentanyl and 100 ng naloxone
Study: 31162856
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) screening, 5 annual rounds
Study: 17939171
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available solid oral dosage pharmaceutical formulations (tablets)
Study: 31190442
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for pediatric acute myeloid leukemia (AML)
Study: 20389255
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 50 mg eq.
Study: 3892729
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg/d
Study: 18936569
Drug: Chronic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic low dose corticosteroid therapy (CCS)
Study: 11703885
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg bid
Study: 2107519
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of Haemophilus influenzae type b conjugate vaccine with measles-mumps-rubella vaccine
Study: 6743785
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral solution
Study: 15923800
Drug: Overall group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall group (all treatments)
Study: 9816717
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 6 ml (Group A)
Study: 8934042
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (estrogen)
Study: 12611172
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of V2 vasopressin receptor agonist (1‐desamino‐8‐D‐arginin‐vasopressin)
Study: 29250537
Drug: Halometasone cream
Normalized name: halometasone
DrugBank: Halometasone (DB13728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halometasone cream (30g daily for 7-14 days) in Group C
Study: 19516150
Drug: Nutrition plus
Normalized name: Liquid Nutrition Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition plus combination of aerobic and strength training (N + CAST)
Study: 10216540
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion for Group I (pulmonary blood flow increase) and Group III (mixing improvement).
Study: 10216540
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion for Group II (systemic blood flow increase).
Study: 26342560
Drug: Droxidopa 600
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droxidopa 600 mg/day for 8 weeks
Study: 29310631
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g CTE with 50 g sucrose in 400 mL of water
Study: 23701526
Drug: XR-NTX 380
Normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX 380 mg
Study: 12771037
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA), 4 g daily for 3 months
Study: 10543808
Drug: L. rhamnosus
Normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. rhamnosus 19070‐2
Study: 22119181
Drug: Mindful awareness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful awareness in body-oriented therapy (MABT)
Study: 23558369
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block (30 mL 0.9% NaCl)
Study: 19920766
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg daily for 2 weeks)
Study: 8791947
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg t.d.s. for the first 2 weeks
Study: 1514724
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg meperidine and 50 mg hydroxyzine
Study: 2439815
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg
Study: 30302901
Drug: Intralesional pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional pentoxifylline (PTX) injection
Study: 27759579
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (600 mg/day)
Study: 15850466
Drug: Lamivudine, 100
Normalized name: LamiVUDine, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine, 100 mg, qd, for 12 months
Study: 26712409
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diluted tincture of opium (DTO)
Study: 30923094
Drug: Bortezomib-dexamethasone induction
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-dexamethasone induction treatment
Study: 14739855
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (n=9) at a continuous rate of >=1.5 microU/kg/min to maintain euglycemia (serum glucose 100‐140 microg/dL)
Study: 14739855
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (n=9)
Study: 25596138
Drug: BUD pMDI
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD pMDI 2 × 160 μg bid
Study: 16330117
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of rofecoxib (n=21)
Study: 8553632
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (control group)
Study: 24879552
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy exercise program for 3 months
Study: 7485297
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available dinoprostone gel 0.5 mg
Study: 18593524
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium DR tablet (500 mg), fasting
Study: 18593524
Drug: VPA DR
Normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA DR soft gelatin capsule (500 mg), fasting
Study: 17300592
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg daily
Study: 17300592
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg daily
Study: 25161155
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg empagliflozin
Study: 19184556
Drug: BIS-augmentation group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-augmentation group (n = 32)
Study: 31666832
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose 1000 mg orally for two days prior to hysterosalpingography
Study: 17209786
Drug: Pregnancy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pregnancy without periodontal treatment
Study: 10869918
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion at a rate of 1 to 2.5 mcg/kg/min to maintain moderate controlled hypotension
Study: 22985137
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration
Study: 29101186
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction ≥40 mm Hg
Study: 20102847
Drug: Whole-grain RTE
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain RTE oat cereal (3 g/day oat b‐glucan)
Study: 19253862
Drug: Ocimum sanctum
Normalized name: Ocimum Sanctum
DrugBank: Ocimum tenuiflorum top (DB14273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocimum sanctum leaf extract (500 mg/capsule, twice daily, p.o. after meal)
Study: 20835552
Drug: Sevoflurane +
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane + 0.1 mg/kg vecuronium
Study: 8589319
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at a dose of 0.125 IU/kg per week for the first 4 weeks and 0.25 IU/kg per week thereafter
Study: 16060200
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug reactions, clinical global impression (CGI), HAMD, mini international psychiatric Interview, Pittsburgh sleep quality index, Side‐effects checklist, Short Form 12, treatment credibility questionnaire, work and social disability scale
Study: 10861309
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate (300000 IU daily for 1 year followed by 150000 IU for a 2nd year)
Study: 6817658
Drug: Inhaled cromoglycate
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled cromoglycate
Study: 27153360
Drug: Fulranumab 10
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 10 mg (10 mgQ4 wk)
Study: 11012556
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (30 microg ethinylestradiol and 75 microg gestodene)
Study: 16472283
Drug: ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 500 mg twice daily for 7 days
Study: 11737926
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin solution (500 ml over 1 h)
Study: 18376350
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load
Study: 26681757
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy
Study: 2162749
Drug: (R)-propafenone hydrochloride
Normalized name: Propafenone Hydrochloride
DrugBank: (R)-Propafenone (DB19162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-propafenone hydrochloride 150 mg
Study: 7800129
Drug: Multidrug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug chemotherapy (6‐thioguanine, dibromodulcitol, procarbazine, 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea, 5‐fluorouracil, and hydroxyurea)
Study: 7800129
Drug: Multidrug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug chemotherapy
Study: 3144919
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patch (0.1 mg, n = 10)
Study: 24800362
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Diclofenac sodium, Anti Spasmodic (Drotverine HCl), Proton Pump inhibitor (Omeprazole 20 mg) once daily)
Study: 11603418
Drug: Spironolactone at
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone at a mean dose of 25 mg/day
Study: 26889783
Drug: Virgin Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin Olive Oil enriched with its own phenolic compounds (FVOO)